JDRF T1D Fund has made an undisclosed investment in TetraGenetics. Based in Arlington, Massachusetts, TetraGenetics is a biopharmaceutical company developing new treatments for autoimmune diseases. Read more >>
Next stage in fish nutrition project moves to large scale field trials. Read More >>
read moreCorbus Pharmaceuticals Holdings, Inc. today announced several changes to its management team. Read more >>
read moreCorbus Pharmaceuticals announces that the European Commission has granted Orphan Designation in the European Union (EU) to lenabasum, its…
read moreCorbus Pharmaceuticals says a Phase 3 clinical trial of anabasum for diffuse cutaneous scleroderma will start in the fourth…
read moreFully launching this spring, Giveback by FutureFuel.io is a payments platform that gives users automatic cashback for student debt…
read moreThanks to the Coronavirus Aid, Relief and Economic Security (CARES) Act, plan sponsors can assist their workers in paying…
read moreWhen Boston-based medical device company Myomo rang the bell of the New York Stock Exchange on June 16, it…
read moreZylö Therapeutics Inc., dedicated to developing a transformational topical delivery platform, announced that on September 21, 2019, it effected…
read moreThe eSight glasses are electronic glasses that have a high speed and high resolution camera in the middle of…
read moreSkyline Medical Inc. (SKLN) (“Skyline” or “the Company”),producer of the FDA-approved STREAMWAY® System for automated, direct-to-drain medical fluid disposal…
read more